Pharmacokinetic interactions of modern antiretroviral therapy

Sinxadi, Phumla Z, Khoo, Saye H ORCID: 0000-0002-2769-0967 and Boffito, Marta
(2021) Pharmacokinetic interactions of modern antiretroviral therapy. AIDS, 35 (Suppl ). S145-S151.

[img] Text
AIDS-D-20-00964_R1.pdf - Author Accepted Manuscript

Download (1MB) | Preview


Drug--drug interactions (DDIs) have been a clinical challenge in HIV medicine for over two decades. The newer antiretroviral drugs (ARTs) have significantly fewer DDIs than protease inhibitors and boosted integrase inhibitors (INSTIs). The lower propensity of such newer antiretrovirals (e.g. unboosted integrase inhibitors; doravirine) to cause DDIs, has been largely offset by the ageing cohort of patients with multiple comorbidities, who are taking multiple chronic medicines. Furthermore, the introduction of newly marketed drugs into clinical practice needs to be closely monitored, as the new drugs may be perpetrators of DDIs, leading to a potential change in the efficacy or toxicity of the coadministered antiretrovirals.

Item Type: Article
Uncontrolled Keywords: dolutegravir--bictegravir--cabotegravir, doravirine, drug interactions, fostemsavir, ibalizumab, low-dose efavirenz, tenofovir alafenamide
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 07 Mar 2022 08:46
Last Modified: 18 Jan 2023 21:11
DOI: 10.1097/QAD.0000000000002950
Related URLs: